<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Systemic therapy of advanced clear cell renal carcinoma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Systemic therapy of advanced clear cell renal carcinoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Systemic therapy of advanced clear cell renal carcinoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel George, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric Jonasch, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael B Atkins, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 31, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Surgical resection of stage I to III renal cell carcinoma (RCC) can be curative, but up to one-third of patients eventually recur. In addition, approximately 15 percent of patients with RCC present with locally advanced or metastatic RCC, for which surgery is noncurative. The natural history of disease for patients with advanced or metastatic RCC can vary widely from a few months to many years depending on the clinical, pathologic, laboratory, and radiographic features of the disease.</p><p>Immunotherapy with checkpoint inhibitors has become a major modality for the treatment of clear cell RCC. This topic will discuss initial systemic therapy for advanced clear cell RCC, with a particular focus on immunotherapy-based combinations. An overview of the treatment approach to clear and non-clear cell RCC, prognostic factors in RCC, and the use of antiangiogenic and molecularly targeted therapy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15719.html" rel="external">"Overview of the treatment of renal cell carcinoma"</a> and  <a class="medical medical_review" href="/z/d/html/2962.html" rel="external">"Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma"</a> and  <a class="medical medical_review" href="/z/d/html/96030.html" rel="external">"The treatment of advanced non-clear cell renal carcinoma"</a>.)</p><p class="headingAnchor" id="H350646872"><span class="h1">RATIONALE FOR IMMUNOTHERAPY</span><span class="headingEndMark"> — </span>Immunotherapy with monoclonal antibodies directed against programmed cell death 1 protein (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) has become an integral part of the management of RCC.</p><p>The fields of immunology and oncology have been linked since the late 19<sup>th</sup> century, when the surgeon William Coley reported that injection of killed bacteria into sites of sarcoma could lead to tumor shrinkage. Since that time, exponential advances in the understanding of the intersection between immune surveillance and tumor growth and development have led to broad therapeutic advances that are now being studied in all cancer types. (See  <a class="medical medical_review" href="/z/d/html/99637.html" rel="external">"Principles of cancer immunotherapy"</a>.)</p><p>Removal of primary RCCs can evoke an immune response that occasionally results in spontaneous and dramatic remissions in metastases, particularly in the lungs [<a href="#rid1">1,2</a>]. These observations were followed by the clinical demonstration of antitumor activity with the cytokine interleukin 2 (IL-2) and interferon alfa (IFNa), although only a minority of patients derived major clinical benefit.</p><p class="headingAnchor" id="H2801796179"><span class="h1">SELECTION OF INITIAL THERAPY</span><span class="headingEndMark"> — </span>Systemic therapy is usually given as a combination of agents from the following classes [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Programmed cell death 1 protein (PD-1) checkpoint inhibitors (<a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> and <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Programmed cell death ligand 1 (PD-L1) checkpoint inhibitors (<a class="drug drug_general" data-topicid="112481" href="/z/d/drug information/112481.html" rel="external">avelumab</a> and <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies (<a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inhibitors of the vascular endothelial growth factor (VEGF) pathway (ie, antiangiogenic agents; <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a>, <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">pazopanib</a>, <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a>, <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a>, and <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mammalian (mechanistic) target of rapamycin (mTOR) inhibitors (<a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>)</p><p></p><p>Interleukin 2 (IL-2) is used less frequently, and interferon alfa (IFNa) has effectively been replaced by other agents. (See <a class="local">'Less preferred treatment options'</a> below.)</p><p>Systemic therapy for patients with previously untreated RCC without brain metastases is discussed below  (<a class="graphic graphic_algorithm graphicRef116262" href="/z/d/graphic/116262.html" rel="external">algorithm 1</a>). Treatment options for those with brain metastases are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15719.html" rel="external">"Overview of the treatment of renal cell carcinoma"</a> and  <a class="medical medical_review" href="/z/d/html/15719.html" rel="external">"Overview of the treatment of renal cell carcinoma", section on 'Brain metastases, treatment naïve'</a>.)</p><p>Importantly, the patterns of response to treatment with immunotherapy agents differ from those with molecularly targeted agents or cytotoxic chemotherapy. (See  <a class="medical medical_review" href="/z/d/html/99637.html" rel="external">"Principles of cancer immunotherapy", section on 'Immunotherapy response criteria'</a>.)</p><p class="headingAnchor" id="H3876174751"><span class="h2">Risk stratification</span><span class="headingEndMark"> — </span>The choice of treatment for patients with advanced disease has been based on prognostic risk factors historically developed in the era of frontline vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (ie, antiangiogenic agents). The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model integrates six adverse factors  (<a class="graphic graphic_table graphicRef116130" href="/z/d/graphic/116130.html" rel="external">table 1</a>) [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Karnofsky performance status (KPS) &lt;80 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Time from diagnosis to treatment &lt;1 year</p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin concentration less than the lower limit of normal</p><p class="bulletIndent1"><span class="glyph">●</span>Serum calcium greater than the upper limit of normal</p><p class="bulletIndent1"><span class="glyph">●</span>Neutrophil count greater than the upper limit of normal</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet count greater than the upper limit of normal</p><p></p><p>Patients with none of these risk factors are considered favorable risk, those with one or two are considered intermediate risk, and those with three or more are considered poor risk.</p><p>In the absence of alternative immunotherapy-based prognostic criteria, the IMDC prognostic criteria continue to be used in the era of immunotherapy, both by clinical trials to risk-stratify patients and by providers and clinical guidelines to direct therapy [<a href="#rid5">5,6</a>].</p><p class="headingAnchor" id="H165212400"><span class="h2">Favorable-risk disease</span><span class="headingEndMark"> — </span>The decision to treat patients with favorable-risk disease takes into account multiple factors, including rate of growth, location of tumor (eg, proximity to vital organs with potential for damage), and symptoms  (<a class="graphic graphic_algorithm graphicRef116262" href="/z/d/graphic/116262.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H1618485340"><span class="h3">Limited disease burden</span><span class="headingEndMark"> — </span>For patients with treatment-naïve, favorable-risk disease with limited disease burden who are asymptomatic, we suggest close active surveillance, with initiation of systemic therapy at onset of new lesions, accelerated growth of existing lesions, or symptomatic disease. (See <a class="local">'Risk stratification'</a> above and <a class="local">'Active surveillance'</a> below.)</p><p>For those with limited burden, favorable-risk disease who desire a more aggressive management approach, options include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Single-agent antiangiogenic therapy</strong> – Single-agent antiangiogenic therapy may be an appropriate treatment option for those who wish to avoid the potential toxicities of immunotherapy-based regimens and/or prefer the convenience of orally administered treatments. Preferred agents include <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> or <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">pazopanib</a>. (See  <a class="medical medical_review" href="/z/d/html/2962.html" rel="external">"Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma", section on 'Inhibitors of the VEGF pathway'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Single-agent immunotherapy</strong> – Single-agent immunotherapy with <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">table 2</a>) or <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef127100" href="/z/d/graphic/127100.html" rel="external">table 3</a>) may be an appropriate treatment option for patients with favorable-risk tumors and limited disease burden who are eligible for immunotherapy, but are not good candidates for ipilimumab-based regimens or antiangiogenic agents. Data on single-agent immunotherapy have demonstrated good clinical response rates and the opportunity for durable responses in this population. However, single-agent immunotherapy does not have regulatory approval as initial therapy in this population. (See <a class="local">'Pembrolizumab'</a> below and <a class="local">'Nivolumab'</a> below.)</p><p></p><p class="headingAnchor" id="H3341571264"><span class="h3">Substantial disease burden</span><span class="headingEndMark"> — </span>Treatment is indicated for those with favorable-risk disease who have more substantial disease burden, are symptomatic, and/or have more rapidly progressive disease. Immunotherapy-based combinations with either <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> plus <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a>, <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a>, or <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> plus pembrolizumab are generally preferred. Although these regimens improve response rates and progression-free survival (PFS), which are important clinical endpoints that translate into a better quality of life, none have shown superior overall survival (OS) compared with <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> in this patient population.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pembrolizumab</strong><strong> plus </strong><strong>axitinib</strong> – <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">Pembrolizumab</a> plus <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a> is one preferred option for patients who are candidates for combined immunotherapy and antiangiogenic therapy. (See <a class="local">'Pembrolizumab plus axitinib'</a> below.)</p><p></p><p class="bulletIndent1">In a phase III trial that included patients with favorable-risk disease, <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> plus <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a> conferred an OS benefit and improved objective response rates (ORRs) and complete response (CR) rates over antiangiogenic therapy alone in the overall population [<a href="#rid7">7-9</a>]. Among the favorable-risk patients, the combination had higher ORRs, but similar PFS and OS compared with antiangiogenic therapy alone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nivolumab</strong><strong> plus </strong><strong>cabozantinib</strong> – In patients who are candidates for combined immunotherapy plus antiangiogenic therapy, <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a> is a reasonable alternative to <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> plus <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a>. This combination is well tolerated [<a href="#rid10">10</a>] and may be preferred in patients who require a rapid treatment response due to substantial, symptomatic disease burden (eg, bony metastases). In a phase III trial that included patients with favorable-risk disease, nivolumab plus cabozantinib improved OS and PFS over antiangiogenic therapy in the overall population and demonstrated clinical efficacy across all IMDC risk subgroups, including longer PFS and ORR in those with favorable-risk disease [<a href="#rid11">11,12</a>]. (See <a class="local">'Nivolumab plus cabozantinib'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lenvatinib</strong><strong> plus </strong><strong>pembrolizumab</strong> – In patients with favorable-risk disease, <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> is another acceptable treatment option. This combination demonstrated higher ORR compared with <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>, with higher PFS and similar OS benefits. However, this regimen has higher toxicity due to lenvatinib (eg, hypertension, proteinuria) and may not be tolerated as well as the above regimens. (See <a class="local">'Lenvatinib plus pembrolizumab'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other strategies</strong> – Alternative strategies include combination therapy with <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>; <a class="drug drug_general" data-topicid="112481" href="/z/d/drug information/112481.html" rel="external">avelumab</a> plus <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a>; or antiangiogenic monotherapy [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nivolumab</strong><strong> plus </strong><strong>ipilimumab</strong> – <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">Nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>  (<a class="graphic graphic_table graphicRef139979" href="/z/d/graphic/139979.html" rel="external">table 4</a>) is a reasonable option for patients who are willing to tolerate the potential toxicities of combination immunotherapy to achieve treatment-free survival. This combination results in sustained CR rates in 13 percent of patients with favorable-risk disease. Among those with favorable-risk disease, nivolumab plus ipilimumab improved treatment-free survival relative to <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> [<a href="#rid14">14</a>] despite having similar OS and lower PFS and ORRs [<a href="#rid15">15</a>]. (See <a class="local">'Nivolumab plus ipilimumab'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Avelumab</strong><strong> plus </strong><strong>axitinib</strong> – In a phase III trial, <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a> plus <a class="drug drug_general" data-topicid="112481" href="/z/d/drug information/112481.html" rel="external">avelumab</a>, relative to antiangiogenic therapy alone, improved PFS and ORRs in those with favorable-risk disease, although an OS benefit has not been established with this approach [<a href="#rid16">16</a>]. Data on CRs and treatment-free survival for the combination are also immature. (See <a class="local">'Avelumab plus axitinib'</a> below.)</p><p></p><p class="headingAnchor" id="H2478406856"><span class="h3">Ineligible for immunotherapy (favorable-risk)</span><span class="headingEndMark"> — </span>Antiangiogenic therapy that incorporates a VEGFR inhibitor may be preferred in those who are ineligible for or who decline immunotherapy. Preferred options include <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">pazopanib</a>, and <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>. An alternative option is <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a>, which is more effective than sunitinib in patients with intermediate- and poor-risk disease but has not been formally evaluated in those with favorable-risk disease. (See  <a class="medical medical_review" href="/z/d/html/2962.html" rel="external">"Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma"</a> and <a class="local">'Lenvatinib plus everolimus'</a> below.)</p><p class="headingAnchor" id="H3228708752"><span class="h2">Intermediate- and poor-risk disease</span><span class="headingEndMark"> — </span>For patients with treatment-naïve intermediate- or poor-risk disease, we recommend checkpoint inhibitor immunotherapy-based regimens over antiangiogenic therapy alone. Our choice of therapy is primarily determined by the presence of symptomatic or life-threatening disease burden and patient clinical characteristics, as follows:</p><p class="headingAnchor" id="H251240896"><span class="h3">Patients with symptomatic or life-threatening disease burden</span><span class="headingEndMark"> — </span>For patients with symptomatic or life-threatening disease burden, we suggest either <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> or <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a> rather than other available agents. Patients with symptomatic tumor involvement of organs such as the liver or bones often require a rapid treatment response, which has been demonstrated by the high ORRs of lenvatinib plus pembrolizumab (71 percent) and nivolumab plus cabozantinib (57 percent), compared with other regimens. Lenvatinib plus pembrolizumab also results in a high CR rate (18 percent) [<a href="#rid17">17-19</a>]. (See <a class="local">'Lenvatinib plus pembrolizumab'</a> below and <a class="local">'Nivolumab plus cabozantinib'</a> below.)</p><p class="headingAnchor" id="H1029369435"><span class="h3">Patients without symptomatic, life-threatening disease burden</span><span class="headingEndMark"> — </span>For those without symptomatic, life-threatening disease burden, we suggest <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>  (<a class="graphic graphic_table graphicRef139979" href="/z/d/graphic/139979.html" rel="external">table 4</a>) rather than combination immunotherapy and antiangiogenic therapy. Nivolumab plus ipilimumab offers the opportunity for curative intent therapy by providing durable responses, preserving OS benefit in extended follow-up, and improving treatment-free survival relative to single-agent <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>. By indirect comparison of randomized trials, nivolumab plus ipilimumab confers these treatment benefits to a greater degree than combination immunotherapy plus antiangiogenic therapy, despite having a relatively lower ORR. (See <a class="local">'Nivolumab plus ipilimumab'</a> below.)</p><p>For patients who are not anticipated to tolerate the toxicities of <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> (eg, those with active autoimmune conditions or limited mobility), the combination of immunotherapy plus antiangiogenic therapy is an appropriate alternative. These regimens have high ORRs and improve OS, but treatment responses are less durable relative to nivolumab plus ipilimumab. Options include <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, nivolumab plus <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a>, or pembrolizumab plus <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a>. (See <a class="local">'Lenvatinib plus pembrolizumab'</a> below and <a class="local">'Nivolumab plus cabozantinib'</a> below and <a class="local">'Pembrolizumab plus axitinib'</a> below.)</p><p>Regimens that combine immunotherapy using PD-1 inhibitors and antiangiogenic therapy have high objective response rates and improve OS compared with single-agent <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>. However, the OS benefit initially seen (eg, with <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> plus <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a> and <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> plus pembrolizumab) diminishes over time (ie, the tails on the OS curves for these combinations versus sunitinib converge). Furthermore, treatment responses are not as durable as those seen with <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>. It is likely that the benefits of combining immunotherapy and antiangiogenic therapy are not additive for immunotherapy-specific endpoints (eg, cure, treatment-free interval, tails on the OS curve). Rather, similar or better results could possibly be achieved by giving immunotherapy alone, followed by antiangiogenic therapy in individuals who do not experience a durable response to the immunotherapy. Patients treated with an initial combination therapy also continue to receive an antiangiogenic agent until disease progression or unacceptable toxicity. In contrast, patients whose disease responds to nivolumab plus ipilimumab have the opportunity for a treatment-free remission after stopping therapy either due to toxicity, CR, or completing planned nivolumab maintenance therapy. (See <a class="local">'Nivolumab plus ipilimumab'</a> below.)</p><p>While <a class="drug drug_general" data-topicid="112481" href="/z/d/drug information/112481.html" rel="external">avelumab</a> plus <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a> has been evaluated as initial therapy, it is <strong>not</strong> one of our preferred regimens since it has not demonstrated an OS benefit in randomized trials  (<a class="graphic graphic_algorithm graphicRef116262" href="/z/d/graphic/116262.html" rel="external">algorithm 1</a>) [<a href="#rid16">16</a>]. (See <a class="local">'Avelumab plus axitinib'</a> below.)</p><p class="headingAnchor" id="H3871005797"><span class="h3">Ineligible for immunotherapy (intermediate- and poor-risk)</span><span class="headingEndMark"> — </span>For those who are ineligible for or choose to forego initial treatment with immunotherapy combinations, regardless of risk category, we offer therapy that incorporates an antiangiogenic agent. While we prefer the combination of <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>, an mTOR inhibitor, as this combination improved PFS over single-agent <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> in a randomized trial [<a href="#rid11">11,12</a>], another reasonable alternative includes <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a>  (<a class="graphic graphic_algorithm graphicRef116262" href="/z/d/graphic/116262.html" rel="external">algorithm 1</a>). (See <a class="local">'Lenvatinib plus everolimus'</a> below and  <a class="medical medical_review" href="/z/d/html/2962.html" rel="external">"Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma", section on 'Preferred VEGFR inhibitors'</a>.)</p><p class="headingAnchor" id="H610168678"><span class="h1">ACTIVE SURVEILLANCE</span><span class="headingEndMark"> — </span>For patients with treatment-naïve, favorable-risk disease who are asymptomatic or minimally symptomatic with limited disease burden, we suggest close active surveillance to determine the pace of disease. Surveillance allows the deferral of therapy and its associated toxicity until more compelling disease progression is documented  (<a class="graphic graphic_algorithm graphicRef116262" href="/z/d/graphic/116262.html" rel="external">algorithm 1</a>).</p><p>Our approach to surveillance is to use computed tomography (CT) imaging of the chest, abdomen, and pelvis every three months for the first year, every four months for the second year, and every six months thereafter. Systemic therapy is initiated at the onset of accelerated disease progression, new lesions, and/or symptomatic disease. (See <a class="local">'Initial treatment options'</a> below.)</p><p>Both observational and trial data support the use of active surveillance [<a href="#rid20">20,21</a>]. As an example, in a prospective phase II trial, 52 patients with treatment-naïve metastatic RCC underwent radiographic surveillance [<a href="#rid20">20</a>]. Median time on surveillance until initiation of systemic therapy was longer for those with favorable-risk disease relative to those with intermediate- or poor-risk disease (22 versus 9 months). There was no impact on rates of depression or anxiety, or on quality of life, based on patient-reported questionnaires.</p><p class="headingAnchor" id="H1689558199"><span class="h1">INITIAL TREATMENT OPTIONS</span></p><p class="headingAnchor" id="H171801769"><span class="h2">Nivolumab plus ipilimumab</span><span class="headingEndMark"> — </span>For patients with advanced RCC without prior exposure to systemic therapy, the combination of <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>  (<a class="graphic graphic_table graphicRef139979" href="/z/d/graphic/139979.html" rel="external">table 4</a>) improves overall survival (OS) compared with <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> and preserves this OS benefit in extended follow-up [<a href="#rid15">15,22-25</a>]. Furthermore, nivolumab plus ipilimumab offers the opportunity for curative intent therapy by improving complete response (CR) rates across all patient subgroups; providing durable responses; and improving treatment-free survival relative to sunitinib [<a href="#rid14">14</a>]. By indirect comparison of randomized trials, nivolumab plus ipilimumab confers these treatment benefits to a greater degree than combination immunotherapy plus an antiangiogenic agent, despite having a lower ORR.</p><p><a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">Nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> is approved by the US Food and Drug Administration (FDA) for treatment-naïve patients with intermediate- or poor-risk advanced RCC. We also use nivolumab plus ipilimumab off label as initial therapy in those with favorable-risk disease who are symptomatic and/or experience interval disease progression while on surveillance. (See <a class="local">'Selection of initial therapy'</a> above.)</p><p>Subsequent maintenance therapy with two years of <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> is also well tolerated, and those who stop therapy for reasons other than disease progression have the opportunity for a prolonged treatment-free interval. The initial use of nivolumab plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> also avoids potential cardiovascular adverse events (eg, hypertension, thrombotic events, wound healing issues) commonly associated with antiangiogenic agents and allows for a wider range of available antiangiogenic therapies upon disease progression. (See  <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">"Cardiovascular toxicities of molecularly targeted antiangiogenic agents"</a> and <a class="local">'Subsequent therapy'</a> below.)</p><p>In an open-label phase III trial (CheckMate 214), 1096 patients with treatment-naïve advanced or metastatic clear cell RCC were randomly assigned to <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> versus <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> [<a href="#rid15">15,22-24,26</a>]. Patients with brain metastases were excluded. The combination of nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) was given every three weeks for four doses, followed by single-agent nivolumab (3 mg/kg or a flat dose of 240 mg  (<a class="graphic graphic_table graphicRef127100" href="/z/d/graphic/127100.html" rel="external">table 3</a>)) every two weeks for up to two years. Sunitinib was given at 50 mg/day for four out of every six weeks.</p><p>At a median follow-up of 68 months, <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>, relative to <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>, had the following results [<a href="#rid15">15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Entire study population</strong> – Improved OS (five-year OS 48 versus 37 percent; hazard ratio [HR] 0.72, 95% CI 0.62-0.85). Progression-free survival (PFS) was higher for the combination, although the results did not meet statistical significance (five-year PFS 30 versus 14 percent; HR 0.86, 95% CI 0.73-1.01). Objective response rates (ORRs; 39 versus 32 percent) and CR rates (12 versus 3 percent) were both higher for the combination. Duration of response (DOR) was also longer for the combination (median not reached versus 20 months, five-year DOR 56 versus 25 percent; HR 0.46, 95% CI 0.31-0.66).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intermediate- or poor-risk disease</strong> – Improved OS and PFS (five-year OS 43 versus 31 percent; HR 0.68, 95% CI 0.58-0.81; five-year PFS 31 versus 11 percent; HR 0.73, 95% CI 0.61-0.87). ORRs (42 versus 27 percent) and CR rates (11 versus 2 percent) were both superior for the combination. Treatment-free survival is also twice as long for the combination (seven versus three months) [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Favorable-risk disease</strong> – Similar OS (five-year OS 63 versus 55 percent; HR 0.94, 95% CI 0.65-1.37) but lower PFS (five-year PFS 26 versus 21 percent, median 12 versus 29 months; HR 1.60, 95% CI 1.13-2.26). Lower ORRs (30 versus 52 percent) but higher CR rates (13 versus 6 percent) were seen for the combination. Despite these outcomes, treatment-free survival is almost three times as long for the combination (11 versus 4 months) [<a href="#rid14">14</a>].</p><p></p><p><a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">Nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> offers the opportunity for curative intent therapy by providing more durable treatment responses than those seen in separate studies of immunotherapy plus antiangiogenic agents (ie, <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> plus <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a> [<a href="#rid9">9</a>] and <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> plus pembrolizumab [<a href="#rid19">19</a>]). Most patients with a complete and/or ongoing treatment response can discontinue all therapy, and many experience prolonged treatment-free survival [<a href="#rid14">14</a>]. (See <a class="local">'Pembrolizumab plus axitinib'</a> below and <a class="local">'Lenvatinib plus pembrolizumab'</a> below.)</p><p>In extended four-year follow-up of CheckMate-214, among those with a CR to <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>, 86 percent (51 of 59 patients) demonstrated ongoing disease response, and approximately half of those with durable responses (27 of 51 patients) discontinued therapy and did not require further treatment at long-term follow-up. Among those with a partial response (PR), 61 percent (95 of 156 patients) also demonstrated ongoing disease response [<a href="#rid22">22</a>].</p><p>Side effects and quality of life data (which is associated with improved OS [<a href="#rid27">27</a>]) also favored the combination of <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> over <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> [<a href="#rid28">28</a>]. The toxicity of this combination was consistent with that observed with its use for other indications. (See  <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors"</a> and  <a class="medical medical_review" href="/z/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation", section on 'Toxicity'</a>.)</p><p class="headingAnchor" id="H188413116"><span class="h2">Pembrolizumab plus axitinib</span><span class="headingEndMark"> — </span>For patients with advanced RCC without prior exposure to systemic therapy, the combination of <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> plus <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a> improves OS and PFS compared with <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>. This combination is approved by the FDA as initial therapy for patients with advanced RCC, regardless of risk stratification. This combination has not been directly compared with other immunotherapy-based combinations.</p><p>For <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> plus <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a>, treatment-related toxicities may be easier to manage due to the dosing flexibility and short half-life of axitinib. In patients who experience treatment-related toxicities on this combination, such as diarrhea or transaminitis, interrupting therapy may allow the clinician to distinguish more easily immunotherapy-related adverse events (which may persist despite stopping treatment) from vascular endothelial growth factor receptor (VEGFR) inhibitor-related toxicities (which may quickly resolve once axitinib is discontinued). (See  <a class="medical medical_review" href="/z/d/html/138429.html" rel="external">"Immune checkpoint inhibitor colitis", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">"Cardiovascular toxicities of molecularly targeted antiangiogenic agents"</a>.)</p><p>In a phase III trial (KEYNOTE-426), 861 patients with previously untreated advanced clear cell RCC were randomly assigned to <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> plus <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a> versus <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> alone [<a href="#rid7">7-9</a>]. Pembrolizumab was administered at 200 mg intravenously every three weeks for up to 35 cycles (approximately two years), whereas axitinib or sunitinib was continued until disease progression or unacceptable toxicity. Patient subgroups included those with favorable-, intermediate-, or poor-risk disease (based on the International Metastatic Renal Cell Carcinoma Database Consortium [IMDC] risk classification) and sarcomatoid features.</p><p>In preliminary results, after a median follow-up of 67 months, relative to <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> plus <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a> had the following results [<a href="#rid7">7-9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Entire study population</strong> – Improved OS, although the benefit diminished over time (median 47 versus 41 months, three-year OS 63 versus 54 percent; four-year OS 49 versus 45 percent; five-year OS 42 versus 37 percent; HR 0.84, 95% CI 0.71-0.99), longer PFS (five-year PFS 18 versus 7 percent; HR 0.69, 95% CI 0.59-0.81), higher objective response rates (ORR) (61 versus 36 percent), and higher CR rate (12 versus 4 percent). The median duration of response (DOR) for the combination versus <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> was 24 and 15 months, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intermediate- or poor-risk disease</strong> – Improved OS (five-year OS 38 versus 30 percent; HR 0.76, 95% CI 0.62-0.93), longer PFS (five-year PFS 18 versus 7 percent; HR 0.68, 95% CI 0.56-0.82), and higher ORRs (46 versus 32 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Favorable-risk disease</strong> – Similar OS (five-year OS 50 versus 52 percent; HR 1.10, 95% CI 0.79-1.54) and PFS (five-year PFS 19 versus 8 percent; HR 0.76, 95% CI 0.57-1.02). ORRs were higher for the combination (69 versus 44 percent).</p><p></p><p>The combination of <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> plus <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a> had slightly higher rates of grade ≥3 adverse events compared with <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> (67 versus 62 percent), but the rate of any grade treatment-related toxicities were lower with the combination than with sunitinib, when adjusted for exposure time (63 versus 97 events per 100 person-months) [<a href="#rid8">8</a>]. In both groups, the most common grade ≥3 adverse events were diarrhea (10 versus 5 percent) and hypertension (22 versus 20 percent). Pembrolizumab plus axitinib demonstrated similar health-related quality of life outcomes compared with sunitinib [<a href="#rid29">29</a>].</p><p>The efficacy of <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> plus <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a> and other immunotherapy-based regimens for those with RCCs containing sarcomatoid features is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/96030.html" rel="external">"The treatment of advanced non-clear cell renal carcinoma", section on 'Non-clear cell RCC with sarcomatoid features'</a>.)</p><p class="headingAnchor" id="H1852063857"><span class="h2">Nivolumab plus cabozantinib</span><span class="headingEndMark"> — </span>For patients with advanced RCC without prior exposure to systemic therapy, the combination of <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> and <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a> improves OS and PFS compared with <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>. This combination is approved by the US FDA as initial therapy for patients with advanced RCC, regardless of risk stratification [<a href="#rid30">30</a>]. This combination has not been directly compared with other immunotherapy-based combination regimens.</p><p>In a phase III trial (CheckMate 9ER), 651 patients with treatment-naïve advanced RCC were randomly assigned to either <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a> or <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> [<a href="#rid11">11,12</a>]. Patient subgroups included those with favorable-, intermediate-, or poor-risk disease (based on the IMDC risk classification).</p><p>At median follow-up of 33 months, compared with <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a> had the following results [<a href="#rid11">11,12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Entire study population</strong> – Improved OS (two-year OS 70 versus 60 percent, median 38 versus 34 months; HR 0.70, 95% CI 0.55-0.90) and PFS (two-year PFS 40 versus 21 percent, median 17 versus 8 months; HR 0.56, 95% CI 0.46-0.68). The combination also demonstrated higher ORR (56 versus 28 percent) and CR rate (12 versus 5 percent). Median time to response was faster with the combination compared with <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> (2.8 versus 4.2 months).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intermediate- or poor-risk disease</strong> – Higher OS (median 38 versus 34 months; HR 0.74, 95% CI 0.54-1.01 for intermediate-risk disease, which was not statistically significant; median 32 versus 11 months, 0.49, 95% CI 0.31-0.79 for poor-risk disease), improved PFS (median 18 versus 9 months; HR 0.54, 95% CI 0.46-0.76 for intermediate-risk disease; median 10 versus 4 months; HR 0.35, 95% CI 0.23-0.55 for poor-risk disease), and higher ORR (57 versus 29 percent for intermediate-risk disease; 38 versus 10 percent for poor-risk disease).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Favorable-risk disease</strong> – Similar OS (HR 1.03, 95% CI 0.55-1.92), longer PFS (median 21 versus 14 months; HR 0.73, 95% CI 0.48-1.11, which is not statistically significant), and higher ORR (66 versus 44 percent).</p><p></p><p>Additionally, PFS benefit results were consistent across all subgroups, including those with positive or negative PD-L1 expression, with or without prior nephrectomy, and with or without bone metastases.</p><p>Grade ≥3 treatment-related adverse events occurred in 65 percent receiving <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a> versus 54 percent receiving <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>. For nivolumab plus cabozantinib, grade ≥3 toxicities included hypertension (13 percent), hyponatremia (9 percent), palmar-plantar erythrodysesthesia (8 percent), diarrhea (7 percent), increased ALT level (5 percent), hypophosphatemia (6 percent), increased AST and proteinuria (4 percent each), and fatigue (3 percent) [<a href="#rid10">10-12</a>].</p><p class="headingAnchor" id="H3999820396"><span class="h2">Lenvatinib combinations</span></p><p class="headingAnchor" id="H3238270959"><span class="h3">Lenvatinib plus pembrolizumab</span><span class="headingEndMark"> — </span>For patients with treatment-naïve advanced RCC, the combination of <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> improved both OS and PFS in a randomized phase III trial [<a href="#rid17">17,18</a>]. Additionally, this combination demonstrated high CR rates. This combination is approved by the US FDA as initial therapy for patients with advanced RCC, regardless of risk stratification [<a href="#rid31">31,32</a>].</p><p>For patients treated with <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, we initiate treatment with full-dose lenvatinib upfront, as reduced doses of VEGFR tyrosine kinase inhibitors, including lenvatinib, have been associated with decreased efficacy. However, we encourage proactive dose adjustment for treatment-related toxicities to maintain quality of life [<a href="#rid33">33-38</a>].</p><p>Based on data from early phase trials [<a href="#rid39">39,40</a>], the combination of <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> was evaluated in an open-label phase III clinical trial (CLEAR) [<a href="#rid17">17,18</a>]. In this study, 1069 patients with treatment-naïve advanced RCC were randomly assigned to either lenvatinib plus pembrolizumab; lenvatinib plus <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>; or <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>. For patients treated with lenvatinib plus pembrolizumab, lenvatinib was given at 20 mg daily and pembrolizumab was given at 200 mg on day 1 of a 21-day cycle for up to 35 cycles (approximately two years). In those treated with lenvatinib plus everolimus, lenvatinib was given at 18 mg daily, and everolimus was given at 5 mg daily on a 21-day cycle.</p><p>At a median follow-up of approximately four years relative to <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>, the combination of <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> demonstrated the following results [<a href="#rid18">18,19</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Entire study population</strong> – Improved OS, although the benefit diminished over time (median 54 months each; two-year OS 80 versus 70 percent; three-year OS 66 versus 60 percent; HR 0.79, 95% CI 0.63-0.99); improved PFS (median 24 versus 9 months; three-year PFS 37 versus 18 percent; HR 0.47, 95% CI 0.38-0.57); and longer DOR (median 27 versus 15 months; HR 0.57, 95% CI 0.43-0.76). ORR was also higher for the combination (71 versus 37 percent), including CR rates (18 versus 4 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intermediate- and poor-risk disease</strong> – Improved PFS (median 22 versus 6 months; HR 0.43, 95% CI 0.34-0.55) and improved OS (median 48 versus 34 months; HR 0.74, 95% CI 0.57-0.96) that was mainly driven by those with poor-risk disease (HR 0.47).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Favorable risk disease</strong> – Improved PFS (median 29 versus 13 months; HR 0.50, 95% CI 0.35-0.71) and similar OS (median not reached versus 60 months; HR 0.94, 95% CI 0.58-1.52).</p><p></p><p>Grade ≥3 adverse events of any cause were higher for the combination compared with <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> (82 versus 72 percent), and no new toxicity profiles were reported [<a href="#rid17">17</a>]. For <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, grade ≥3 toxicities included hypertension (28 percent), diarrhea (10 percent), weight decrease or proteinuria (8 percent each), and palmar-plantar erythrodysesthesia syndrome (4 percent).</p><p><a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">Lenvatinib</a> plus <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> also demonstrated similar or more favorable health-related quality of life outcomes compared with <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> [<a href="#rid41">41</a>]. However, the similar quality of life outcomes between the two treatment arms suggest an increase in treatment-related toxicity from lenvatinib plus pembrolizumab, despite its increased clinical efficacy and reduction of tumor-related symptoms.</p><p class="headingAnchor" id="H131606007"><span class="h3">Lenvatinib plus everolimus</span><span class="headingEndMark"> — </span>In the randomized phase III trial (CLEAR), among patients with treatment-naïve RCC, the combination of <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> improved PFS (median 15 versus 9 months; HR 0.65, 95% CI 0.53-0.8) over <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>, which was consistent across all IMDC subgroup [<a href="#rid17">17</a>]. ORR was also higher for the combination (54 versus 36 percent), including CR rates (10 versus 4 percent). However, OS was not higher for the combination (medians not reached; HR 1.15, 95% CI 0.88-1.5). Grade ≥3 adverse events of any cause were higher for the combination compared with sunitinib (83 versus 72 percent).</p><p>Data for <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> as subsequent therapy in patients with advanced RCC who have progressed on antiangiogenic therapy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2962.html" rel="external">"Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma", section on 'Lenvatinib plus everolimus'</a>.)</p><p class="headingAnchor" id="H1471474498"><span class="h2">Other strategies</span><span class="headingEndMark"> — </span>While some other combinations have suggested activity, they have yet to show an OS benefit. Initial data regarding these combinations are presented below.</p><p class="headingAnchor" id="H2774196768"><span class="h3">Avelumab plus axitinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">Axitinib</a> has also been shown to combine safely and effectively with the checkpoint inhibitor <a class="drug drug_general" data-topicid="112481" href="/z/d/drug information/112481.html" rel="external">avelumab</a>, and this is an option for first-line therapy. However, we prefer other immunotherapy combinations over axitinib plus avelumab for patients without a contraindication to immunotherapy. In separate randomized trials, axitinib plus avelumab improved PFS, but not OS, in all patient subgroups relative to <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>, whereas both survival outcomes were improved and simultaneously evident for the other two combination regimens. These three regimens have not been directly compared in a single randomized trial. (See <a class="local">'Nivolumab plus ipilimumab'</a> above and <a class="local">'Pembrolizumab plus axitinib'</a> above.)</p><p>Based on data from early phase clinical trials [<a href="#rid42">42,43</a>], <a class="drug drug_general" data-topicid="112481" href="/z/d/drug information/112481.html" rel="external">avelumab</a> plus <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a> was evaluated in a phase III trial (JAVELIN Renal 101). In this study, 886 treatment-naïve patients with advanced clear cell RCC were randomly assigned to the combination of avelumab plus axitinib versus <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> [<a href="#rid16">16,44</a>].</p><p>At a median follow-up of approximately 19 months, compared with <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="112481" href="/z/d/drug information/112481.html" rel="external">avelumab</a> plus <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a> demonstrated the following results by population:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Entire study population</strong> – Improved PFS (median 13.3 versus 8 months; HR 0.69, 95% CI 0.57-0.83) and higher ORRs (53 versus 27 percent). CR rates were similar for the two treatment arms (4 versus 2 percent). Although OS data are immature, the combination did not demonstrate an improvement in OS at data cutoff for the overall population (HR 0.80, 95% CI 0.62-1.03) or for any other patient subgroup.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PD-L1-positive tumors</strong> – Improved PFS (median 13.8 versus 7 months; HR 0.62, 95% CI 0.49-0.78) and higher ORRs (56 versus 27 percent) and CR rates (6 versus 2 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Favorable-risk disease</strong> – Improved PFS (HR 0.63, 95% CI 0.4-0.99) and higher ORRs (67 versus 40 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intermediate- or poor-risk disease</strong> – Improved PFS (HR 0.76, 95% CI 0.6-0.95, for intermediate-risk disease; HR 0.51, 95% CI 0.34-0.77, for poor-risk disease) and higher ORRs (53 versus 27 percent for intermediate-risk disease; 32 versus 13 percent for poor-risk disease).</p><p></p><p>Rates of grade ≥3 toxicities were similar between the two groups (71 percent each), with the most common toxicities including hypertension (26 versus 17 percent), diarrhea (7 versus 3 percent), fatigue (4 percent each), and palmar-plantar erythrodysesthesia (6 versus 4 percent). The most frequent immune-mediated adverse event in those treated with <a class="drug drug_general" data-topicid="112481" href="/z/d/drug information/112481.html" rel="external">avelumab</a> plus <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a> was immune-related thyroid disorders (25 percent). Major cardiovascular toxicities occurred more frequently in those treated with the combination of avelumab plus axitinib compared with <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> (7 versus 4 percent) [<a href="#rid45">45</a>] and included grade ≥3 myocardial infarction (3 percent), congestive heart failure (2 percent), and death due to cardiac events (1 percent) [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">"Cardiovascular toxicities of molecularly targeted antiangiogenic agents"</a>.)</p><p>Based on the results of this trial, the combination of <a class="drug drug_general" data-topicid="112481" href="/z/d/drug information/112481.html" rel="external">avelumab</a> plus <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a> was approved by the US FDA for first-line treatment of patients with advanced RCC.</p><p class="headingAnchor" id="H1339430887"><span class="h3">Pembrolizumab</span><span class="headingEndMark"> — </span>Single-agent immunotherapy with <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">table 2</a>) was studied in the KEYNOTE-427 trial [<a href="#rid47">47</a>]. In Cohort A of that study, 110 patients with advanced or metastatic clear cell RCC were treated with pembrolizumab (200 mg every three weeks). All patients had measurable disease and had not received prior systemic therapy. PD-L1 status was assessed using a combined positive score (CPS).</p><p>In the total study population, the ORR was 36 percent, which included 4 patients with a CR and 36 patients with a PR. The response rate was higher in patients with intermediate- or poor-risk disease compared with those with favorable-risk disease (40 versus 31 percent). Additionally, CPS ≥1 percent was associated with higher response rates. Two-year PFS and OS were 22 and 71 percent, respectively.</p><p class="headingAnchor" id="H509961360"><span class="h3">Nivolumab</span><span class="headingEndMark"> — </span>Single-agent immunotherapy with <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef127100" href="/z/d/graphic/127100.html" rel="external">table 3</a>) has activity in treatment-naïve advanced or metastatic clear cell RCC with response rates of up to 34 percent. These data are based on phase II trials evaluating a response-adapted strategy of initial therapy with single-agent nivolumab and salvage therapy with nivolumab plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> in those without an objective response to nivolumab alone [<a href="#rid48">48-50</a>].</p><p>As an example, in a nonrandomized phase II trial (HCRN GU16-260), 123 patients with treatment-naïve metastatic clear cell RCC received single-agent <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>. Patients with objective responses (either partial or complete) continued nivolumab for up to two years or treatment intolerance [<a href="#rid49">49</a>]. Patients with either stable disease at one year or progressive disease received subsequent salvage therapy with nivolumab plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>, followed by maintenance nivolumab for up to one year.</p><p class="bulletIndent1"><span class="glyph">●</span>At median follow-up of 28 months, among those treated with <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>, the ORR was 34 percent, median PFS was approximately eight months, and two-year OS was 78 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Compared with those with intermediate- or poor-risk disease, patients with favorable-risk disease had a higher PFS (median 32 versus 5 months) and ORR (57 versus 25 percent). In a subsequent preliminary analysis, at three years from enrollment, patients with favorable-risk disease also had longer treatment-free survival compared with those with intermediate- or poor-risk disease (mean 13 versus 8 months) [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Median DOR was at least 28 months for all patients and 11 months for those with intermediate-risk disease. Of note, responses are ongoing in 17 of 20 (85 percent) patients with favorable-risk disease and three of four (75 percent) patients with poor-risk disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among the 35 patients who received salvage therapy with <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>, objective responses were seen in four patients (11 percent).</p><p></p><p>A separate phase II trial (OMNIVORE) used a similar response-adapted treatment approach in a similar population; in this study, the ORRs for initial therapy with <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> and salvage therapy with nivolumab plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> were 17 and 4 percent, respectively [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H2788680400"><span class="h3">Atezolizumab plus bevacizumab</span><span class="headingEndMark"> — </span>There is no established role for <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a> plus <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> in patients with metastatic RCC. Based on results from a phase II study [<a href="#rid52">52</a>], a randomized phase III trial (IMmotion151) comparing atezolizumab plus bevacizumab with <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> was conducted in 915 treatment-naïve patients with advanced or metastatic RCC [<a href="#rid53">53,54</a>]. In the entire study population, compared with sunitinib, atezolizumab plus bevacizumab improved PFS (median 11 versus 8 months; HR 0.83, 95% CI 0.70-0.97) [<a href="#rid53">53</a>] but did not confer an OS benefit [<a href="#rid54">54</a>].</p><p>Although <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a> plus <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> did not show sufficient clinical advantages over antiangiogenic therapy to merit regulatory approval, these data provide valuable information about predictive biomarkers for response to angiogenesis inhibitors and immunotherapy. These biomarkers may ultimately be used to guide patient selection for subsequently approved regimens [<a href="#rid53">53-56</a>].</p><p class="headingAnchor" id="H3059188783"><span class="h2">Less preferred treatment options</span></p><p class="headingAnchor" id="H1279446623"><span class="h3">Interleukin 2 and other interleukins</span><span class="headingEndMark"> — </span>Immunotherapy with high-dose bolus interleukin 2 (IL-2) can activate an immune response against RCC, which results in tumor regression in a minority of patients. Although treatment is associated with severe toxicity, responses often persist for many years, even in the absence of additional therapy, and the majority of complete responders remain free of relapse long term.</p><p>While high-dose IL-2 was considered an important option for carefully selected patients who were able to tolerate the toxicity associated with this approach and who had access to this treatment, its current role in the setting of more active and better tolerated checkpoint inhibitor immunotherapy approaches is undefined. IL-2 still could be an option in patients whose disease has progressed on initial immunotherapy-based regimens [<a href="#rid57">57-59</a>]. Other interleukins that have been evaluated include IL-4 [<a href="#rid60">60</a>], IL-6 [<a href="#rid61">61</a>], pegylated IL-10 [<a href="#rid62">62</a>], and IL-12 [<a href="#rid63">63,64</a>]. The encouraging results seen in animal studies with the combination of IL-12 plus IL-2 [<a href="#rid65">65</a>] have not been confirmed in human clinical trials [<a href="#rid66">66</a>].</p><p>In seven phase II studies, high-recombinant IL-2 was administered as an intravenous infusion every eight hours over five consecutive days for two cycles beginning on days 1 and 15. Responding patients and those with stable disease were retreated approximately every 12 weeks for a maximum of three courses [<a href="#rid57">57,58</a>]. In a combined analysis of 259 patients, 30 PRs (12 percent) and 23 CRs (9 percent) were seen. Among the patients who achieved a CR, 19 of 23 (83 percent) remained free of recurrence at last follow-up. The four patients who relapsed all did so within the first four years after treatment. By contrast, all patients who had a PR eventually recurred, predominantly within the first three years. Similar results were seen in another series of 212 patients treated with high-dose IL-2, in which an overall response rate of 20 percent was observed. This included 16 patients (8 percent) with a CR and a median survival of over 10 years [<a href="#rid67">67</a>].</p><p>Results from several large randomized trials subsequently provided additional support for this approach compared with lower dose schedules of IL-2 and combinations with interferon alfa (IFNa) [<a href="#rid68">68,69</a>].</p><p>However, treatment with IL-2 was associated with severe toxicity affecting multiple organ systems  (<a class="graphic graphic_table graphicRef67823 graphicRef80320" href="/z/d/graphic/67823.html" rel="external">table 5A-B</a>) [<a href="#rid70">70</a>]. These complications included hypotension, cardiac arrhythmia, metabolic acidosis, fever, nausea and vomiting, dyspnea, edema, oliguria and renal failure, neurotoxicity, and dermatologic complications. Use of high-dose regimens required treatment in a setting where blood pressure support could be provided. Several experimental approaches were tried in an effort to separate the toxicity of IL-2 from its antitumor activity, but these approaches did not prove useful in a clinical setting [<a href="#rid71">71-78</a>].</p><p class="headingAnchor" id="H521752455"><span class="h3">Interferon alpha</span><span class="headingEndMark"> — </span>The use of interferon alpha (interferon alpha-2a and interferon alpha-2b) has largely been replaced by immunotherapy with checkpoint inhibitors and molecularly targeted agents. Data suggest minimal efficacy for this agent in patients with metastatic RCC [<a href="#rid79">79-85</a>]. Additionally, access to interferon alpha-2b is limited as the manufacturer has discontinued production of this agent.</p><p class="headingAnchor" id="H2107074562"><span class="h3">Nivolumab plus ipilimumab and cabozantinib</span><span class="headingEndMark"> — </span>We do not offer the triplet combination of <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> and <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a> as initial therapy for metastatic RCC. In a randomized trial, this combination improved progression-free survival but increased toxicity.</p><p><a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">Nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> and <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a> was evaluated in a phase III trial (COSMIC-313) of 855 patients with treatment-naïve, IMDC intermediate- or high-risk metastatic clear cell RCC. At median follow-up of 20 months, the addition of cabozantinib to nivolumab plus ipilimumab improved progression-free survival (PFS; median not reached versus 11 months; hazard ratio 0.73, 95% CI 0.57-0.94), and objective response rates (43 versus 36 percent), but increased grade ≥3 toxicity (79 versus 56 percent) [<a href="#rid86">86</a>]. Subgroup analyses suggest that clinical benefit for the combination is primarily seen in those with intermediate-risk disease. Data for overall survival are immature.</p><p class="headingAnchor" id="H861781481"><span class="h1">SUBSEQUENT THERAPY</span><span class="headingEndMark"> — </span>The choice of therapy at relapse is dependent on prior therapy received.</p><p class="headingAnchor" id="H1290397708"><span class="h2">Prior immunotherapy with or without antiangiogenic therapy</span><span class="headingEndMark"> — </span>For patients who progress after initial immunotherapy containing regimen, with or without prior antiangiogenic therapy, we recommend subsequent therapy with an antiangiogenic agent rather than the combination of immunotherapy plus an antiangiogenic agent, as the latter approach does not improve progression-free survival (PFS) or overall survival (OS) and increases toxicity.</p><p>While we prefer <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a> (if not previously administered) [<a href="#rid87">87-89</a>], other options include <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a>, <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">pazopanib</a>, <a class="drug drug_general" data-topicid="131053" href="/z/d/drug information/131053.html" rel="external">tivozanib</a>, or <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> with <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>. (See  <a class="medical medical_review" href="/z/d/html/2962.html" rel="external">"Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma", section on 'Preferred VEGFR inhibitors'</a>.)</p><p>Patients may also be offered combined <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>  (<a class="graphic graphic_table graphicRef139979" href="/z/d/graphic/139979.html" rel="external">table 4</a>) if they have no prior exposure to ipilimumab [<a href="#rid90">90</a>]. The addition of ipilimumab to nivolumab may "boost" response rates after progression on single-agent nivolumab, as was demonstrated in the TITAN-RCC (Tailored ImmunoTherapy Approach with Nivolumab in advanced Renal Cell Carcinoma) study [<a href="#rid50">50</a>] as well as other studies [<a href="#rid49">49,90,91</a>]. As data are limited for this approach, clinical trial enrollment is encouraged. (See <a class="local">'Nivolumab plus ipilimumab'</a> above.)</p><p>Based on initial studies [<a href="#rid89">89</a>], an open-label, randomized phase III trial (CONTACT-3) was conducted to evaluate <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a> plus <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a> versus cabozantinib alone in 522 patients advanced or metastatic renal cell carcinoma who had progressed on immunotherapy with or without antiangiogenic therapy [<a href="#rid87">87</a>]. All patients recently progressed on immunotherapy (either as first- or second-line therapy or within six months of completing adjuvant immunotherapy) and had no prior treatment with cabozantinib or more than one immunotherapy agent. Among the 520 patients who progressed on first-line therapy, <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> was used most frequently (29 percent); followed by <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> plus <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a> (12 percent); nivolumab monotherapy (3 percent); <a class="drug drug_general" data-topicid="112481" href="/z/d/drug information/112481.html" rel="external">avelumab</a> plus axitinib, <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> plus pembrolizumab, and bempegaldesleukin plus nivolumab (2 percent each). Among the 244 patients who progressed on second-line therapy, nivolumab was used most frequently (90 percent) after initial therapy with <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> or <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">pazopanib</a> (29 and 15 percent, respectively), followed by nivolumab plus ipilimumab (3 percent) and pembrolizumab plus axitinib (2 percent). Only two patients progressed after adjuvant immunotherapy.</p><p>At median follow-up of 15 months, the addition of <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a> to <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a> failed to improve PFS (median 11 months each; HR 1.03, 95% CI 0.83-1.28) or OS (median OS 26 months versus not evaluable; HR 0.94, 95% CI 0.70-1.27). The addition of atezolizumab to cabozantinib also increased toxicity (grade ≥3 toxicity 56 versus 47 percent; serious treatment-related adverse events 24 versus 12 percent). Limitations of this study include the use of atezolizumab (a programmed cell death ligand 1 [PD-L1] inhibitor) that has not conferred an OS benefit in the treatment of advanced RCC, and the immediate rechallenge with immunotherapy, which may have been inhibited by long-term programmed cell death 1 (PD-1) receptor occupancy from the prior immunotherapy agent.</p><p class="headingAnchor" id="H2784375050"><span class="h2">Prior antiangiogenic therapy alone</span><span class="headingEndMark"> — </span>For patients who progress on initial treatment with an antiangiogenic agent alone and without previous exposure to checkpoint inhibitor immunotherapy, we suggest treatment with <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> rather than further targeted therapy  (<a class="graphic graphic_table graphicRef127100" href="/z/d/graphic/127100.html" rel="external">table 3</a>). Although data are limited, we also offer the combination of nivolumab plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>  (<a class="graphic graphic_table graphicRef139979" href="/z/d/graphic/139979.html" rel="external">table 4</a>) as an alternative option, based on phase I data from the CheckMate 016 trial and other observational data [<a href="#rid90">90,92</a>]. (See <a class="local">'Nivolumab'</a> below and <a class="local">'Nivolumab plus ipilimumab'</a> above.)</p><p>For those who are ineligible for immunotherapy, we offer an alternative vascular endothelial growth factor receptor (VEGFR) inhibitor. (See  <a class="medical medical_review" href="/z/d/html/2962.html" rel="external">"Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma", section on 'Preferred VEGFR inhibitors'</a>.)</p><p class="headingAnchor" id="H3938376564"><span class="h3">Nivolumab</span><span class="headingEndMark"> — </span>For those who progress on initial treatment with an antiangiogenic agent alone without previous exposure to checkpoint inhibitor immunotherapy, we suggest treatment with <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef127100" href="/z/d/graphic/127100.html" rel="external">table 3</a>). Nivolumab improves overall survival (OS), progression-free survival (PFS), objective response rates (ORR), and quality of life compared with <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> in this population.</p><p>In the phase III CheckMate 025 trial, 821 patients were randomly assigned to <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> (3 mg/kg every two weeks) or <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> (10 mg/day) [<a href="#rid93">93-97</a>]. All patients had received one or two prior antiangiogenic therapies. With a median follow-up of 64 months, relative to everolimus, single-agent nivolumab resulted in the following [<a href="#rid97">97</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Improved OS (median 25.8 versus 19.7 months, five-year OS 26 versus 18 percent, hazard ratio [HR] 0.73, 95% CI 0.62-0.85), regardless of PD-L1 expression and other prognostic factors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Improved five-year PFS (5 versus 1 percent; HR 0.84, 95% CI 0.72-0.99), although median PFS was similar between the two groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Higher ORR (23 versus 4 percent), including rare complete responses (CRs; 1 versus 0.5 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Longer treatment-free interval among responders who came off treatment without subsequent systemic therapy (12.7 versus 4.1 months).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lower rate of grade ≥3 toxicity (21 versus 37 percent) and improved quality of life in extended follow-up. The most frequent grade ≥3 toxicities were fatigue and anemia (2 percent each).</p><p></p><p>Additional responses may be seen if <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> is continued after initial progression. In the CheckMate 025 study, nivolumab therapy was also permitted after Response Evaluation Criteria in Solid Tumors (RECIST) progression if clinical benefit was observed [<a href="#rid96">96</a>]. If subsequent assessment confirmed disease progression, therapy was discontinued. In total, 78 percent (316 of 406) of patients treated with nivolumab had progressed, and 48 percent (153 of 316) of these patients were treated for ≥4 weeks after first progression. Post-progression, 13 percent of patients who continued on nivolumab treatment experienced ≥30 percent tumor burden reduction from first progression. The actual contribution of the continued therapy to these delayed responses remains to be determined.</p><p class="headingAnchor" id="H2773118301"><span class="h2">Prior immunotherapy and antiangiogenic therapy</span></p><p class="headingAnchor" id="H2807119788"><span class="h3">Belzutifan</span><span class="headingEndMark"> — </span>For patients who progress on both immunotherapy and antiangiogenic therapy, we offer <a class="drug drug_general" data-topicid="132401" href="/z/d/drug information/132401.html" rel="external">belzutifan</a>, a small molecule inhibitor of hypoxia-inducible factor 2 alpha (HIF-2a). In patients with treatment-refractory clear cell RCC, belzutifan improves PFS with an acceptable toxicity profile [<a href="#rid98">98</a>]. This agent is also used to treat patients with von Hippel-Lindau disease-related clear cell RCC, hemangioblastomas, and pancreatic neuroendocrine tumors. (See  <a class="medical medical_review" href="/z/d/html/5193.html" rel="external">"Clinical features, diagnosis, and management of von Hippel-Lindau disease"</a>.)</p><p>Based on data from phase I and II trials [<a href="#rid99">99-101</a>], <a class="drug drug_general" data-topicid="132401" href="/z/d/drug information/132401.html" rel="external">belzutifan</a> was evaluated in an open-label phase III trial (LITESPARK-005) of 746 patients with advanced or metastatic clear cell RCC who progressed on up to three lines or prior therapy, including an immune checkpoint inhibitor and antiangiogenic therapy [<a href="#rid98">98</a>]. Patients were randomly assigned to either belzutifan 120 mg orally once daily or <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> 10 mg orally once daily. In preliminary results, at median follow-up of 26 months, relative to everolimus, belzutifan improved PFS (median 5.6 months each, 18-month PFS 23 versus 9 percent; HR 0.74, 95% CI 0.63-0.88) and ORRs (23 versus 4 percent). OS was similar between the two treatment arms (median 21 versus 18 months; HR 0.88, 95% CI 0.73-1.07). Although grade ≥3 toxicities were similar in both treatment arms (62 percent each), belzutifan was discontinued less frequently due to toxicity (6 versus 15 percent).</p><p><a class="drug drug_general" data-topicid="132401" href="/z/d/drug information/132401.html" rel="external">Belzutifan</a> is approved by the US Food and Drug Administration (FDA) for advanced RCC following treatment with a PD-1 or PD-L1 inhibitor and a VEGF tyrosine kinase inhibitor [<a href="#rid102">102</a>].</p><p class="headingAnchor" id="H3208511768"><span class="h1">SPECIAL CONSIDERATIONS</span></p><p class="headingAnchor" id="H2412189266"><span class="h2">Cytoreductive (debulking) nephrectomy</span><span class="headingEndMark"> — </span>In the era of effective checkpoint inhibitor immunotherapy and antiangiogenic therapy, the role of cytoreductive or debulking nephrectomy (ie, removal of the primary tumor) is limited to select treatment-naïve patients with metastatic RCC. The criteria for selecting patients for cytoreductive nephrectomy prior to initiation of immunotherapy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2963.html" rel="external">"Role of surgery in patients with metastatic renal cell carcinoma", section on 'Patient selection for cytoreductive nephrectomy'</a>.)</p><p>Although initial data supported this approach prior to administration of interferon alfa (IFNa) [<a href="#rid81">81,103,104</a>], the addition of cytoreductive nephrectomy to antiangiogenic therapy in those with treatment-naïve metastatic disease did not improve overall survival (OS) in two randomized trials [<a href="#rid105">105,106</a>]. Additionally, in a subgroup analysis of the CheckMate 214 trial, prior nephrectomy was not associated with improved survival outcomes among patients treated with <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> [<a href="#rid24">24</a>].</p><p>These and other data on cytoreductive nephrectomy in those with metastatic RCC are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2963.html" rel="external">"Role of surgery in patients with metastatic renal cell carcinoma", section on 'Cytoreductive nephrectomy'</a>.)</p><p class="headingAnchor" id="H3784130799"><span class="h2">Brain metastases</span><span class="headingEndMark"> — </span>The treatment approach to patients with brain metastases from renal cell carcinoma is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15719.html" rel="external">"Overview of the treatment of renal cell carcinoma", section on 'Brain metastases, treatment naïve'</a>.)</p><p class="headingAnchor" id="H2430930743"><span class="h2">Bone metastases</span><span class="headingEndMark"> — </span>For patients with renal cell carcinoma metastatic to bone, we offer a bone resorption inhibitor to reduce the risk of pathologic fractures and other skeletal-related events [<a href="#rid107">107</a>]. Options include either a bisphosphonate (such as <a class="drug drug_general" data-topicid="9736" href="/z/d/drug information/9736.html" rel="external">pamidronate</a>, <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a>, or <a class="drug drug_general" data-topicid="8887" href="/z/d/drug information/8887.html" rel="external">ibandronate</a>) or a receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor (such as <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a>). Patients should be counseled on the potential risks of bone resorption inhibitors prior to initiating therapy, which are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2806.html" rel="external">"Risks of therapy with bone antiresorptive agents in patients with advanced malignancy"</a>.)</p><p class="headingAnchor" id="H167754026"><span class="h2">Patients with chronic kidney disease</span><span class="headingEndMark"> — </span>Most patients with chronic kidney disease (CKD) at baseline can be safely treated with systemic regimens used for advanced or metastatic RCC [<a href="#rid108">108</a>]. Immune checkpoint inhibitors (ICIs; such as <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>, <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>, and <a class="drug drug_general" data-topicid="112481" href="/z/d/drug information/112481.html" rel="external">avelumab</a>) are antibodies that do not require dose adjustments for baseline altered kidney function, including end-stage kidney disease. For antiangiogenic agents (such as <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a>, <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a>, and <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a>), clinicians should adjust the dose of therapy as needed based on the patient's baseline kidney function. (See  <a class="medical medical_review" href="/z/d/html/2359.html" rel="external">"Assessment of kidney function"</a>.)</p><p>Similar to the general population, patients with CKD should be closely monitored for nephrotoxicity after treatment initiation, such as ICI-associated acute kidney injury and proteinuria or nephrotic syndrome with antiangiogenic agents. Further details on these toxicities are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'Kidney'</a> and  <a class="medical medical_review" href="/z/d/html/114914.html" rel="external">"Nephrotoxicity of molecularly targeted agents and immunotherapy", section on 'Antiangiogenic agents'</a>.)</p><p class="headingAnchor" id="H29"><span class="h1">EXPERIMENTAL APPROACHES</span></p><p class="headingAnchor" id="H1927225410"><span class="h2">Pembrolizumab plus bevacizumab</span><span class="headingEndMark"> — </span>The combination of <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> plus <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> has efficacy in patients with metastatic RCC, but this approach remains investigational. In an open-label phase II trial of 48 treatment-naïve patients, the ORR for this combination was 61 percent, including one patient with a complete response; median PFS was 21 months [<a href="#rid109">109</a>]. There were no unexpected toxicities; the toxicity profile mirrored that of the individual agents.</p><p class="headingAnchor" id="H766815099"><span class="h2">Nivolumab plus axitinib</span><span class="headingEndMark"> — </span>The combination of <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a> has efficacy in patients with metastatic RCC, but this approach remains investigational. In preliminary results of a phase I/II trial of 44 patients with treatment-naïve advanced RCC, the ORR for this combination was approximately 69 percent [<a href="#rid110">110</a>].</p><p class="headingAnchor" id="H2871480410"><span class="h2">Vaccines</span><span class="headingEndMark"> — </span>Approaches to re-engage immune recognition of tumor through autologous cellular immunotherapy have no established role in the treatment of those with advanced RCC. The addition of rocapuldencel-T (an autologous dendritic cell immunotherapy) to <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> did not improve OS in a phase III trial, despite promising results from an earlier phase II trial [<a href="#rid111">111,112</a>]. Similarly, the addition of a cancer vaccine (IMA901) to sunitinib did not improve OS in a similar patient population [<a href="#rid113">113</a>].</p><p class="headingAnchor" id="H1923370144"><span class="h2">Biomarkers for selecting therapy</span><span class="headingEndMark"> — </span>The use of biomarkers and gene expression profiling to prospectively select patients with advanced RCC for systemic therapy has been investigated in a phase II trial (BIONIKK) [<a href="#rid114">114</a>]. Further data are needed before incorporating the use of biomarkers into routine clinical practice.</p><p class="headingAnchor" id="H1222174509"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/119821.html" rel="external">"Society guideline links: Cancer of the kidney and ureters"</a>.)</p><p class="headingAnchor" id="H37"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/888.html" rel="external">"Patient education: Renal cell carcinoma (kidney cancer) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H38"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for treatment in advanced renal cell carcinoma</strong> – For most patients with advanced clear cell renal cell carcinoma (RCC), systemic therapy is typically initiated promptly when unresectable disease, either metastatic or locally advanced, is present. The decision to start systemic therapy and the selection of agent(s) depend on disease-related symptoms, patient comorbidities, and tumor risk stratification  (<a class="graphic graphic_algorithm graphicRef116262" href="/z/d/graphic/116262.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef116130" href="/z/d/graphic/116130.html" rel="external">table 1</a>). (See <a class="local">'Selection of initial therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Favorable-risk disease with limited disease burden</strong> – For patients with treatment-naïve, favorable-risk disease with limited disease burden, we suggest close active surveillance, rather than initiation of systemic therapy, to determine the pace of disease (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Surveillance allows the deferral of therapy and its associated toxicity until more compelling disease progression is documented. (See <a class="local">'Limited disease burden'</a> above and <a class="local">'Active surveillance'</a> above.)</p><p></p><p class="bulletIndent1">Alternatively, for those with limited disease burden who desire a more aggressive management approach, options include either single-agent antiangiogenic therapy (typically <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> or <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">pazopanib</a>) or single-agent immunotherapy (with either <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>  (<a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">table 2</a>) or <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef127100" href="/z/d/graphic/127100.html" rel="external">table 3</a>)). (See <a class="local">'Limited disease burden'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of initial systemic therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Favorable-risk disease, substantial disease burden</strong> – For patients with treatment-naïve, favorable-risk disease who are symptomatic and/or have more rapidly progressive disease, we suggest either <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> plus <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a>, <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a>, or <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> plus pembrolizumab rather than other regimens (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Substantial disease burden'</a> above and <a class="local">'Pembrolizumab plus axitinib'</a> above and <a class="local">'Nivolumab plus cabozantinib'</a> above and <a class="local">'Lenvatinib plus pembrolizumab'</a> above.)</p><p></p><p class="bulletIndent2">Other acceptable options include <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>  (<a class="graphic graphic_table graphicRef139979" href="/z/d/graphic/139979.html" rel="external">table 4</a>) (for those willing to tolerate the potential toxicities of immunotherapy to potentially achieve a complete response [CR]) and <a class="drug drug_general" data-topicid="112481" href="/z/d/drug information/112481.html" rel="external">avelumab</a> plus <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a> (which improves progression-free survival [PFS] and objective response rates [ORR], although an overall survival [OS] benefit has not been established). (See <a class="local">'Substantial disease burden'</a> above and <a class="local">'Nivolumab plus ipilimumab'</a> above and <a class="local">'Avelumab plus axitinib'</a> above.)</p><p></p><p class="bulletIndent2">Antiangiogenic therapy that incorporates a vascular endothelial growth factor receptor (VEGFR) inhibitor is also an alternative option in patients who are ineligible for or decline immunotherapy. (See <a class="local">'Ineligible for immunotherapy (favorable-risk)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intermediate- or poor-risk disease</strong> – For patients with treatment-naïve intermediate- or poor-risk disease, we recommend checkpoint inhibitor immunotherapy-based regimens over antiangiogenic therapy alone (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Our choice of therapy is primarily determined by the presence of symptomatic or life-threatening disease burden and patient clinical characteristics. (See <a class="local">'Intermediate- and poor-risk disease'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Patients with symptomatic or life-threatening disease burden</strong> – For patients with symptomatic or life-threatening disease burden, we suggest either <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> or <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a> rather than other regimens (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>) due to higher ORRs in randomized trials, to obtain a rapid treatment response. (See <a class="local">'Patients with symptomatic or life-threatening disease burden'</a> above and <a class="local">'Lenvatinib plus pembrolizumab'</a> above and <a class="local">'Nivolumab plus cabozantinib'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Patients without symptomatic, life-threatening disease burden</strong> – For patients without symptomatic or life-threatening disease burden, we suggest <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>  (<a class="graphic graphic_table graphicRef139979" href="/z/d/graphic/139979.html" rel="external">table 4</a>) rather than combination immunotherapy and antiangiogenic therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), as this approach offers the opportunity for curative intent therapy by providing durable responses, preserving OS benefit, and improving treatment-free survival. (See <a class="local">'Patients without symptomatic, life-threatening disease burden'</a> above and <a class="local">'Nivolumab plus ipilimumab'</a> above.)</p><p></p><p class="bulletIndent3">For those who are not anticipated to tolerate the toxicities of <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> (eg, those with active autoimmune conditions or limited mobility), the combination of immunotherapy plus antiangiogenic therapy is an appropriate alternative. Options include <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, nivolumab plus <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a>, or pembrolizumab plus <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a>. These regimens have high ORR and improve OS, but responses are less durable than nivolumab plus ipilimumab. (See <a class="local">'Lenvatinib plus pembrolizumab'</a> above and <a class="local">'Nivolumab plus cabozantinib'</a> above and <a class="local">'Pembrolizumab plus axitinib'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ineligible for immunotherapy (intermediate- or poor-risk disease)</strong> – For those with intermediate- and poor-risk disease who are ineligible for or choose to forego initial treatment with immunotherapy combinations, we offer therapy that incorporates an antiangiogenic agent. Preferred options include <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> or <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a>. (See <a class="local">'Ineligible for immunotherapy (intermediate- and poor-risk)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent therapy</strong> – For patients who progress after initial therapy, the choice of treatment depends on prior therapy (see <a class="local">'Subsequent therapy'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prior immunotherapy, with or without an antiangiogenic agent</strong> – For patients who progress after an initial immunotherapy containing regimen, with or without prior antiangiogenic therapy, we recommend subsequent therapy with an antiangiogenic agent rather than the combination of immunotherapy plus an antiangiogenic agent (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>), as the latter approach failed to improve OS and increased toxicity in a randomized trial While we prefer <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a> (if not previously administered), other options include <a class="drug drug_general" data-topicid="17141" href="/z/d/drug information/17141.html" rel="external">axitinib</a>, <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">pazopanib</a>, <a class="drug drug_general" data-topicid="131053" href="/z/d/drug information/131053.html" rel="external">tivozanib</a>, and <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> plus <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>. (See <a class="local">'Prior immunotherapy with or without antiangiogenic therapy'</a> above.)</p><p></p><p class="bulletIndent2">Patients may also be offered combined <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>  (<a class="graphic graphic_table graphicRef139979" href="/z/d/graphic/139979.html" rel="external">table 4</a>) if they have no prior exposure to this combination. (See <a class="local">'Nivolumab plus ipilimumab'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prior antiangiogenic agent alone</strong> – For patients who progress after initial treatment with an antiangiogenic agent without previous exposure to immunotherapy, we suggest <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>  (<a class="graphic graphic_table graphicRef127100" href="/z/d/graphic/127100.html" rel="external">table 3</a>) rather than further lines of targeted therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), as nivolumab improved overall survival over <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> in this setting. Although data are limited, we also offer the combination of nivolumab plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>  (<a class="graphic graphic_table graphicRef139979" href="/z/d/graphic/139979.html" rel="external">table 4</a>) as an alternative option. (See <a class="local">'Nivolumab'</a> above and <a class="local">'Nivolumab plus ipilimumab'</a> above.)</p><p></p><p class="bulletIndent2">For those who are ineligible for immunotherapy, we offer an alternative antiangiogenic agent. (See  <a class="medical medical_review" href="/z/d/html/2962.html" rel="external">"Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma", section on 'Preferred VEGFR inhibitors'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prior immunotherapy and antiangiogenic therapy</strong> – For patients who progress on both immunotherapy and antiangiogenic therapy, we offer <a class="drug drug_general" data-topicid="132401" href="/z/d/drug information/132401.html" rel="external">belzutifan</a>, a small molecule inhibitor of hypoxia-inducible factor 2 alpha (HIF-2a). (See <a class="local">'Belzutifan'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. J Urol 1992; 148:1247.</a></li><li><a class="nounderline abstract_t">Gleave ME, Elhilali M, Fradet Y, et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 1998; 338:1265.</a></li><li><a class="nounderline abstract_t">Hofmann F, Hwang EC, Lam TB, et al. Targeted therapy for metastatic renal cell carcinoma. Cochrane Database Syst Rev 2020; 10:CD012796.</a></li><li><a class="nounderline abstract_t">Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 2013; 14:141.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Kidney cancer. https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf (Accessed on October 22, 2019).</li><li><a class="nounderline abstract_t">Ernst MS, Navani V, Wells JC, et al. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur Urol 2023; 84:109.</a></li><li><a class="nounderline abstract_t">Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2019; 380:1116.</a></li><li><a class="nounderline abstract_t">Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol 2020; 21:1563.</a></li><li><a class="nounderline abstract_t">Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426. J Clin Oncol 2023; 41; 17S.</a></li><li><a class="nounderline abstract_t">Cella D, Motzer RJ, Suarez C, et al. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. Lancet Oncol 2022; 23:292.</a></li><li><a class="nounderline abstract_t">Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2021; 384:829.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol 2022; 23:888.</a></li><li><a class="nounderline abstract_t">Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol 2019; 30:706.</a></li><li><a class="nounderline abstract_t">Regan MM, Jegede OA, Mantia CM, et al. Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. Clin Cancer Res 2021; 27:6687.</a></li><li><a class="nounderline abstract_t">Motzer RJ, McDermott DF, Escudier B, et al. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer 2022; 128:2085.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2019; 380:1103.</a></li><li><a class="nounderline abstract_t">Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med 2021; 384:1289.</a></li><li><a class="nounderline abstract_t">Choueiri TK, Eto M, Motzer R, et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol 2023; 24:228.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Porta C, Eto M, et al. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. J Clin Oncol 2024; :JCO2301569.</a></li><li><a class="nounderline abstract_t">Rini BI, Dorff TB, Elson P, et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol 2016; 17:1317.</a></li><li><a class="nounderline abstract_t">Harrison MR, Costello BA, Bhavsar NA, et al. Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). Cancer 2021; 127:2204.</a></li><li><a class="nounderline abstract_t">Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 2020; 5:e001079.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 2018; 378:1277.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 2019; 20:1370.</a></li><li><a class="nounderline abstract_t">Escudier B, Motzer RJ, Tannir NM, et al. Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. Eur Urol 2020; 77:449.</a></li><li><a class="nounderline abstract_t">Albiges L, Tannir NM, Burotto M, et al. First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. Eur Urol 2022; 81:266.</a></li><li><a class="nounderline abstract_t">Cella D, Choueiri TK, Hamilton M, et al. The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214. Oncologist 2024.</a></li><li><a class="nounderline abstract_t">Cella D, Grünwald V, Escudier B, et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncol 2019; 20:297.</a></li><li><a class="nounderline abstract_t">Bedke J, Rini BI, Plimack ER, et al. Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma. Eur Urol 2022; 82:427.</a></li><li class="breakAll">Nivolumab: US Food and Drug Administration (FDA) Prescribing Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125554s119lbl.pdf (Accessed on February 20, 2023).</li><li class="breakAll">Pembrolizumab: United States Food and Drug Administration Prescribing Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s136lbl.pdf (Accessed on April 12, 2023).</li><li class="breakAll">Lenvatinib: United States Food and Drug Administration Prescribing Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206947s019lbl.pdf (Accessed on August 12, 2021).</li><li><a class="nounderline abstract_t">Pal SK, Puente J, Heng DYC, et al. Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial. Eur Urol 2022; 82:283.</a></li><li><a class="nounderline abstract_t">Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2016; 387:2008.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Russo P, Haas N, et al. Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. Eur Urol 2021; 79:334.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Hutson TE, Olsen MR, et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 2012; 30:1371.</a></li><li><a class="nounderline abstract_t">Jonasch E, Slack RS, Geynisman DM, et al. Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol 2018; 36:1588.</a></li><li><a class="nounderline abstract_t">Alam R, Patel HD, Su ZT, et al. Self-reported quality of life as a predictor of mortality in renal cell carcinoma. Cancer 2022; 128:479.</a></li><li><a class="nounderline abstract_t">Taylor MH, Lee CH, Makker V, et al. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. J Clin Oncol 2020; 38:1154.</a></li><li><a class="nounderline abstract_t">Lee CH, Shah AY, Rasco D, et al. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncol 2021; 22:946.</a></li><li><a class="nounderline abstract_t">Motzer R, Porta C, Alekseev B, et al. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Lancet Oncol 2022; 23:768.</a></li><li><a class="nounderline abstract_t">Choueiri TK, Larkin J, Oya M, et al. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol 2018; 19:451.</a></li><li><a class="nounderline abstract_t">Larkin J, Oya M, Martignoni M, et al. Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial. Oncologist 2023; 28:333.</a></li><li><a class="nounderline abstract_t">Choueiri TK, Motzer RJ, Rini BI, et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol 2020; 31:1030.</a></li><li><a class="nounderline abstract_t">Rini BI, Moslehi JJ, Bonaca M, et al. Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. J Clin Oncol 2022; 40:1929.</a></li><li class="breakAll">US Food and Drug Administration Label for Axitinib. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202324s011lbl.pdf (Accessed on June 08, 2020).</li><li><a class="nounderline abstract_t">McDermott DF, Lee JL, Bjarnason GA, et al. Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. J Clin Oncol 2021; 39:1020.</a></li><li><a class="nounderline abstract_t">McKay RR, McGregor BA, Xie W, et al. Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). J Clin Oncol 2020; 38:4240.</a></li><li><a class="nounderline abstract_t">Atkins MB, Jegede OA, Haas NB, et al. Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). J Clin Oncol 2022; 40:2913.</a></li><li><a class="nounderline abstract_t">Grimm MO, Esteban E, Barthélémy P, et al. Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2023; 24:1252.</a></li><li><a class="nounderline abstract_t">Atkins MAB, Jegede O, McDermott DF, Haas NG. Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A). J Clin Oncol 2023; 41;6S.</a></li><li><a class="nounderline abstract_t">Powles T, Atkins MB, Escudier B, et al. Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. Eur Urol 2021; 79:665.</a></li><li><a class="nounderline abstract_t">Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 2019; 393:2404.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Powles T, Atkins MB, et al. Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. JAMA Oncol 2022; 8:275.</a></li><li><a class="nounderline abstract_t">Saal J, Bald T, Hölzel M, et al. In the phase III IMmotion151 trial of metastatic renal cell carcinoma the easy-to-implement modified Glasgow prognostic score predicts outcome more accurately than the IMDC score. Ann Oncol 2022; 33:982.</a></li><li><a class="nounderline abstract_t">Saal J, Bald T, Eckstein M, et al. Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma. JAMA Oncol 2023; 9:1048.</a></li><li><a class="nounderline abstract_t">Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13:688.</a></li><li><a class="nounderline abstract_t">Klapper JA, Downey SG, Smith FO, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 2008; 113:293.</a></li><li><a class="nounderline abstract_t">Buchbinder EI, Dutcher JP, Daniels GA, et al. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. J Immunother Cancer 2019; 7:49.</a></li><li><a class="nounderline abstract_t">Margolin K, Aronson FR, Sznol M, et al. Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. J Immunother Emphasis Tumor Immunol 1994; 15:147.</a></li><li><a class="nounderline abstract_t">Weiss GR, Margolin KA, Sznol M, et al. A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma. J Immunother Emphasis Tumor Immunol 1995; 18:52.</a></li><li><a class="nounderline abstract_t">Naing A, Wong DJ, Infante JR, et al. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol 2019; 20:1544.</a></li><li><a class="nounderline abstract_t">Atkins MB, Robertson MJ, Gordon M, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997; 3:409.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Rakhit A, Schwartz LH, et al. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res 1998; 4:1183.</a></li><li><a class="nounderline abstract_t">Wigginton JM, Komschlies KL, Back TC, et al. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst 1996; 88:38.</a></li><li><a class="nounderline abstract_t">Gollob JA, Veenstra KG, Parker RA, et al. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol 2003; 21:2564.</a></li><li><a class="nounderline abstract_t">Belldegrun AS, Klatte T, Shuch B, et al. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Cancer 2008; 113:2457.</a></li><li><a class="nounderline abstract_t">Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21:3127.</a></li><li><a class="nounderline abstract_t">McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23:133.</a></li><li><a class="nounderline abstract_t">Schwartz RN, Stover L, Dutcher J. Managing toxicities of high-dose interleukin-2. Oncology (Williston Park) 2002; 16:11.</a></li><li><a class="nounderline abstract_t">Mier JW, Vachino G, Klempner MS, et al. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood 1990; 76:1933.</a></li><li><a class="nounderline abstract_t">Vetto JT, Papa MZ, Lotze MT, et al. Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids. J Clin Oncol 1987; 5:496.</a></li><li><a class="nounderline abstract_t">Trehu EG, Mier JW, Dubois JS, et al. Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera. Clin Cancer Res 1996; 2:1341.</a></li><li><a class="nounderline abstract_t">Du Bois JS, Trehu EG, Mier JW, et al. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J Clin Oncol 1997; 15:1052.</a></li><li><a class="nounderline abstract_t">Margolin K, Atkins M, Sparano J, et al. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma. Clin Cancer Res 1997; 3:565.</a></li><li><a class="nounderline abstract_t">McDermott DF, Trehu EG, Mier JW, et al. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor. Clin Cancer Res 1998; 4:1203.</a></li><li><a class="nounderline abstract_t">Kilbourn RG, Fonseca GA, Trissel LA, Griffith OW. Strategies to reduce side effects of interleukin-2: evaluation of the antihypotensive agent NG-monomethyl-L-arginine. Cancer J Sci Am 2000; 6 Suppl 1:S21.</a></li><li><a class="nounderline abstract_t">Samlowski WE, Petersen R, Cuzzocrea S, et al. A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects. Nat Med 2003; 9:750.</a></li><li><a class="nounderline abstract_t">Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. N Engl J Med 1998; 338:1272.</a></li><li><a class="nounderline abstract_t">Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999; 353:14.</a></li><li><a class="nounderline abstract_t">Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345:1655.</a></li><li><a class="nounderline abstract_t">Minasian LM, Motzer RJ, Gluck L, et al. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1993; 11:1368.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20:289.</a></li><li><a class="nounderline abstract_t">Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; :CD001425.</a></li><li><a class="nounderline abstract_t">Gore ME, Griffin CL, Hancock B, et al. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet 2010; 375:641.</a></li><li><a class="nounderline abstract_t">Choueiri TK, Powles T, Albiges L, et al. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. N Engl J Med 2023; 388:1767.</a></li><li><a class="nounderline abstract_t">Pal SK, Albiges L, Tomczak P, et al. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet 2023; 402:185.</a></li><li><a class="nounderline abstract_t">McGregor BA, Lalani AA, Xie W, et al. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. Eur J Cancer 2020; 135:203.</a></li><li><a class="nounderline abstract_t">Pal SK, McGregor B, Suárez C, et al. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. J Clin Oncol 2021; 39:3725.</a></li><li><a class="nounderline abstract_t">Gul A, Stewart TF, Mantia CM, et al. Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors. J Clin Oncol 2020; 38:3088.</a></li><li><a class="nounderline abstract_t">Ravi P, Mantia C, Su C, et al. Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. JAMA Oncol 2020; 6:1606.</a></li><li><a class="nounderline abstract_t">Hammers HJ, Plimack ER, Infante JR, et al. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. J Clin Oncol 2017; 35:3851.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015; 373:1803.</a></li><li><a class="nounderline abstract_t">Cella D, Grünwald V, Nathan P, et al. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Lancet Oncol 2016; 17:994.</a></li><li><a class="nounderline abstract_t">Escudier B, Sharma P, McDermott DF, et al. CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. Eur Urol 2017.</a></li><li><a class="nounderline abstract_t">Escudier B, Motzer RJ, Sharma P, et al. Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. Eur Urol 2017; 72:368.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Escudier B, George S, et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer 2020; 126:4156.</a></li><li><a class="nounderline abstract_t">Albiges L, Rini BI, Peltola K, De Velasco Oria. https://www.annalsofoncology.org/article/S0923-7534(23)04234-5/fulltext. Ann Oncol 2023; 34;2S.</a></li><li><a class="nounderline abstract_t">Choueiri TK, Bauer TM, Papadopoulos KP, et al. Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat Med 2021; 27:802.</a></li><li><a class="nounderline abstract_t">Choueiri TK, McDermott DF, Merchan J, et al. Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study. Lancet Oncol 2023; 24:553.</a></li><li><a class="nounderline abstract_t">Jonasch E, Bauer TM, Papadopoulos KP, et al. Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort. Eur J Cancer 2024; 196:113434.</a></li><li class="breakAll">DailyMed Drug Information: https://dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on January 30, 2024).</li><li><a class="nounderline abstract_t">Elhilali MM, Gleave M, Fradet Y, et al. Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma. The Canadian Urologic Oncology Group. BJU Int 2000; 86:613.</a></li><li><a class="nounderline abstract_t">Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358:966.</a></li><li><a class="nounderline abstract_t">Méjean A, Ravaud A, Thezenas S, et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med 2018; 379:417.</a></li><li><a class="nounderline abstract_t">Bex A, Mulders P, Jewett M, et al. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncol 2019; 5:164.</a></li><li><a class="nounderline abstract_t">Rathmell WK, Rumble RB, Van Veldhuizen PJ, et al. Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. J Clin Oncol 2022; 40:2957.</a></li><li><a class="nounderline abstract_t">Tiu BC, Strohbehn IA, Zhao S, et al. Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study. Oncologist 2023; 28:e379.</a></li><li><a class="nounderline abstract_t">Dudek AZ, Liu LC, Gupta S, et al. Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003. J Clin Oncol 2020; 38:1138.</a></li><li><a class="nounderline abstract_t">Zibelman MR, Carducci MA, Ged Y, et al. A phase I/II study of nivolumab and axitinib in patients with advanced renal cell carcinoma. J Clin Oncol 2022; 40;6S.</a></li><li><a class="nounderline abstract_t">Amin A, Dudek AZ, Logan TF, et al. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. J Immunother Cancer 2015; 3:14.</a></li><li class="breakAll">Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT) - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01582672 (Accessed on October 24, 2019).</li><li><a class="nounderline abstract_t">Rini BI, Stenzl A, Zdrojowy R, et al. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol 2016; 17:1599.</a></li><li><a class="nounderline abstract_t">Vano YA, Elaidi R, Bennamoun M, et al. Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet Oncol 2022; 23:612.</a></li></ol></div><div id="topicVersionRevision">Topic 2984 Version 109.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1404646" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9562580" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33058158" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Targeted therapy for metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23312463" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23312463" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36707357" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30779529" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33284113" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35032437" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33657295" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35688173" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30788497" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34759043" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35383908" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30779531" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33616314" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36858721" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38227898" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27498080" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33765337" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33246931" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29562145" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31427204" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31732098" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34750035" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38280218" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30658932" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35843776" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35843776" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35843776" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35843776" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35210132" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26969090" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33461782" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22430274" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29641297" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34609761" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Self-reported quality of life as a predictor of mortality in renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31961766" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34143969" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35489363" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29530667" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36576173" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32339648" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35239416" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35239416" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33529051" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33108238" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35442713" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37844597" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33678522" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31079938" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34940781" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35716906" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : In the phase III IMmotion151 trial of metastatic renal cell carcinoma the easy-to-implement modified Glasgow prognostic score predicts outcome more accurately than the IMDC score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37347489" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7884429" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18457330" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30777131" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8136948" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8535571" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31563517" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9815699" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9607576" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8847724" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12829677" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18823034" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12915604" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15625368" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12469935" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Managing toxicities of high-dose interleukin-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2242421" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3493332" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9816306" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9060545" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9815721" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9607578" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10685654" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Strategies to reduce side effects of interleukin-2: evaluation of the antihypotensive agent NG-monomethyl-L-arginine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12730689" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9562581" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10023944" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11759643" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8315435" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11773181" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15674877" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Immunotherapy for advanced renal cell cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20153039" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37163623" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37290461" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32599410" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34491815" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32491962" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32469396" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28678668" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26406148" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27283863" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28262413" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28410865" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32673417" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : https://www.annalsofoncology.org/article/S0923-7534(23)04234-5/fulltext</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33888901" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Inhibition of hypoxia-inducible factor-2αin renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37011650" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38008031" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38008031" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11069364" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma. The Canadian Urologic Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11583750" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29860937" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30543350" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35728020" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36821637" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32097091" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : A phase I/II study of nivolumab and axitinib in patients with advanced renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25901286" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25901286" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27720136" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35390339" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
